Therapix Biosciences Ltd. | CIK:0001611746 | 3

  • Filed: 4/30/2018
  • Entity registrant name: Therapix Biosciences Ltd. (CIK: 0001611746)
  • Generator: GoXBRL
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1611746/000121390018005176/0001213900-18-005176-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1611746/000121390018005176/trpx-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001611746
  • Open this page in separate window: Click
  • ifrs-full:DisclosureOfEarningsPerShareExplanatory

    NOTE 18:- LOSS PER SHARE OR ADS

     

      a. Details of the number of shares or ADS and loss used in the computation of loss per share or ADS:

     

          Year ended December 31,  
          2017     2016     2015  
         

    Weighted

    number of

    shares/ADSs

        Loss    

    Weighted

    number of

    shares/ADSs

        Loss    

    Weighted

    number of

    shares/ADSs

        Loss  
         

    In

    thousands

        USD in thousands    

    In

    thousands

        USD in thousands    

    In

    thousands

        USD in thousands  
                                           
      Amounts used in the computation of basic and diluted  loss per share     116,743     $ (6,244 )     37,458     $ (2,007 )     23,853     $ (2,617 )
                                                       
      Amounts used in the computation of basic and diluted  loss per ADS     2,919     $ (6,244 )     936     $ (2,007 )     596     $ (2,617 )

     

      b. The computation of diluted loss per share or ADS did not include the following convertible securities since their inclusion would decrease the loss per share (anti-dilutive effect):
         
      c.  

     

      1. Share or ADS options to employees, officers, directors and consultants.

     

      2. Non-marketable warrants to investor.